Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC BNO 1095 in Cyclic Mastodynia and PMS
NCT01870687Phase 3Terminated
- Sponsor
- Bionorica
- Start
- Jun 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in premenstrual syndrome (PMS) and Mastodynia comparing VAC BNO 1095 with Placebo (2 arms). Primary endpoint: Maximum severity of cyclic breast pain at 3 months. Started Jun 2013; status: terminated.
02
Drugs
vitex agnus-castus fruit extract
03
Conditions
premenstrual syndrome (PMS)Mastodynia
Beyond the preview
Go deeper on NCT01870687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870687.